A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

NCT07343960 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate Hepatic Impairment

Interventions

DRUG: Capivasertib

Sponsor

AstraZeneca

Collaborators

[object Object]